Posted by Michael Wonder on 28 May 2021
U.S. Food and Drug Administration approves Bristol Myers Squibb’s Zeposia (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis
27 May 2021 - Bristol Myers Squibb is committed to making Zeposia accessible to appropriate patients who need it through the Zeposia 360 Support program.
Bristol Myers Squibb today announced that the U.S. FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.
